费城染色体阳性白血病中的靶向治疗与T315I突变 - Suppr

Suppr

超能文献

Targeted therapy and the T315I mutation in Philadelphia-positive leukemias.

作者信息

Soverini Simona, Iacobucci Ilaria, Baccarani Michele, Martinelli Giovanni

出版信息

Haematologica. 2007 Apr;92(4):437-9. doi: 10.3324/haematol.11248.

DOI:10.3324/haematol.11248

PMID:17488653

Abstract

摘要

相似文献

Targeted therapy and the T315I mutation in Philadelphia-positive leukemias.费城染色体阳性白血病中的靶向治疗与T315I突变

Haematologica. 2007 Apr;92(4):437-9. doi: 10.3324/haematol.11248.

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.慢性髓性白血病中的新型Bcr-Abl抑制剂：控制耐药性

Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865.

Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.韩国慢性髓性白血病患者在接受 Abl 酪氨酸激酶抑制剂治疗期间 T315I BCR-ABL 激酶结构域突变的动态变化。

Hematol Oncol. 2010 Jun;28(2):82-8. doi: 10.1002/hon.918.

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.费城染色体阳性白血病患者对达沙替尼的耐药性以及BCR-ABL激酶结构域中315和317位残基处突变的存在或选择。

Haematologica. 2007 Mar;92(3):401-4. doi: 10.3324/haematol.10822.

Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.第二代酪氨酸激酶抑制剂作为慢性髓性白血病的治疗方法。

Curr Hematol Malig Rep. 2007 May;2(2):83-8. doi: 10.1007/s11899-007-0012-4.

Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.一名对STI571耐药性增加的慢性髓性白血病患者中BCR-ABL的ATP结合位点发生突变。

Br J Haematol. 2002 Oct;119(1):109-11. doi: 10.1046/j.1365-2141.2002.03708.x.

Circumventing resistance to kinase-inhibitor therapy.规避对激酶抑制剂疗法的耐药性。

N Engl J Med. 2006 Jun 15;354(24):2594-6. doi: 10.1056/NEJMe068073.

Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.附加染色体异常和 BCR-ABL 激酶结构域突变对费城染色体阳性慢性髓性白血病患者接受尼罗替尼治疗反应的影响。

Haematologica. 2010 Apr;95(4):582-8. doi: 10.3324/haematol.2009.014712. Epub 2009 Dec 16.

Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.对来自印度的慢性髓性白血病病例中赋予对酪氨酸激酶抑制剂耐药性的ABL激酶结构域突变的分析。

Clin Lab. 2011;57(7-8):619-23.

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.博舒替尼、达沙替尼和尼罗替尼对18种伊马替尼耐药的BCR/ABL突变体的活性。

J Clin Oncol. 2009 Jan 20;27(3):469-71. doi: 10.1200/JCO.2008.19.8853. Epub 2008 Dec 15.

引用本文的文献

Tyrosine Kinase Inhibitor Post-Allogeneic Stem Cell Transplantation in Adult Philadelphia-Positive B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions.酪氨酸激酶抑制剂在成人费城染色体阳性B细胞急性淋巴细胞白血病异基因造血干细胞移植后的应用：现状与未来方向

Curr Issues Mol Biol. 2025 Feb 18;47(2):129. doi: 10.3390/cimb47020129.

Olverembatinib combined with inotuzumab ozogamicin in relapsed refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: A case report.奥雷巴替尼联合伊妥珠单抗治疗复发难治费城染色体阳性急性淋巴细胞白血病：一例报告。

Medicine (Baltimore). 2024 Jul 19;103(29):e38985. doi: 10.1097/MD.0000000000038985.

Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia.溶酶体酸性脂肪酶A调节慢性髓性白血病急变期白血病干细胞对维奈托克/酪氨酸激酶抑制剂联合治疗的反应。

Haematologica. 2025 Jan 1;110(1):103-116. doi: 10.3324/haematol.2023.284716.

CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions.慢性髓性白血病对第二代 TKI 的耐药：机制、下一步和新方向。

Curr Hematol Malig Rep. 2022 Dec;17(6):198-205. doi: 10.1007/s11899-022-00683-3. Epub 2022 Oct 20.

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors.在对酪氨酸激酶抑制剂呈现BCR::ABL1非依赖性耐药的慢性粒细胞白血病细胞中，Polo样激酶-1、极光激酶A和WEE1激酶是有前景的可成药靶点。

Front Oncol. 2022 Aug 5;12:901132. doi: 10.3389/fonc.2022.901132. eCollection 2022.

Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia.克服对激酶抑制剂的耐药性：慢性髓性白血病的范例

Onco Targets Ther. 2022 Jan 25;15:103-116. doi: 10.2147/OTT.S289306. eCollection 2022.

A Review on the Therapeutic Role of TKIs in Case of CML in Combination With Epigenetic Drugs.酪氨酸激酶抑制剂（TKIs）联合表观遗传药物治疗慢性粒细胞白血病（CML）的作用综述

Front Genet. 2021 Oct 22;12:742802. doi: 10.3389/fgene.2021.742802. eCollection 2021.

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis.波那替尼和其他 CML 酪氨酸激酶抑制剂在血栓形成中的作用。

Int J Mol Sci. 2020 Sep 8;21(18):6556. doi: 10.3390/ijms21186556.

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia.慢性期慢性髓性白血病患者使用波纳替尼的最佳方法的见解。

Ther Adv Hematol. 2019 Mar 1;10:2040620719826444. doi: 10.1177/2040620719826444. eCollection 2019.

Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.帕比司他与波纳替尼联合使用可协同克服伊马替尼耐药的慢性粒细胞白血病细胞。

Cancer Sci. 2016 Jul;107(7):1029-38. doi: 10.1111/cas.12965. Epub 2016 Jun 21.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验